贝伐珠单抗在转移性乳腺癌中的应用：何时可以使用？
Bevacizumab in metastatic breast cancer: when may it be used?
机构信息
Memorial Sloan-Kettering Cancer Center, Medicine and Epidemiology and Biostatistics, New York, NY, USA.
出版信息
Ther Adv Med Oncol. 2011 Mar;3(2):85-93. doi: 10.1177/1758834010397627.
Abstract
Tumor angiogenesis, which is necessary for breast cancer growth, invasion and metastases, is regulated by pro-angiogenic factors such as vascular endothelial growth factor (VEGF). Bevacizumab is a recombinant humanized monoclonal antibody that targets VEGF. The addition of bevacizumab to chemotherapy has improved progression-free survival in the first- and second-line treatment of patients with advanced-stage breast cancer. In this article we review the clinical trials testing the utility of bevacizumab for the treatment of metastatic disease.
摘要
肿瘤血管生成对于乳腺癌的生长、侵袭和转移是必需的，它受到血管内皮生长因子（VEGF）等促血管生成因子的调控。贝伐珠单抗是一种靶向 VEGF 的重组人源化单克隆抗体。贝伐珠单抗联合化疗在晚期乳腺癌一线和二线治疗中改善了无进展生存期。本文回顾了临床试验，以评估贝伐珠单抗治疗转移性疾病的疗效。
相似文献
1
Bevacizumab in metastatic breast cancer: when may it be used?贝伐珠单抗在转移性乳腺癌中的应用：何时可以使用？
Ther Adv Med Oncol. 2011 Mar;3(2):85-93. doi: 10.1177/1758834010397627.
2
Bevacizumab for advanced breast cancer.贝伐单抗用于晚期乳腺癌
Womens Health (Lond). 2010 Jan;6(1):17-25. doi: 10.2217/whe.09.71.
3
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.针对内分泌难治性或耐药性转移性乳腺癌的血管内皮生长因子（VEGF）靶向治疗。
Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD008941. doi: 10.1002/14651858.CD008941.pub2.
4
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.血管内皮生长因子（VEGF）作为贝伐单抗在癌症治疗中的靶点：从生物学机制到临床应用
Curr Med Chem. 2006;13(16):1845-57. doi: 10.2174/092986706777585059.
5
Integration of novel agents in the treatment of colorectal cancer.新型药物在结直肠癌治疗中的整合应用。
Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. doi: 10.1007/s00280-004-0884-0.
6
Vascular endothelial growth factor and bevacitumab in breast cancer.血管内皮生长因子与贝伐单抗在乳腺癌中的应用
Breast Cancer. 2007;14(2):163-73. doi: 10.2325/jbcs.968.
7
Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.VEGF-A剪接变体mRNA表达与贝伐单抗治疗的转移性乳腺癌患者预后的相关性
Clin Breast Cancer. 2014 Oct;14(5):330-8. doi: 10.1016/j.clbc.2014.02.009. Epub 2014 Mar 1.
8
Angiogenesis as a therapeutic target in breast cancer.血管生成作为乳腺癌的治疗靶点。
Mini Rev Med Chem. 2012 Oct;12(12):1230-8. doi: 10.2174/138955712802761988.
9
Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?转移性乳腺癌患者使用贝伐珠单抗治疗：它还有作用吗？
Curr Treat Options Oncol. 2012 Jun;13(2):249-62. doi: 10.1007/s11864-012-0181-9.
10
Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.抗血管生成治疗联合应用可减少实验性乳腺癌骨转移中的骨质溶解和肿瘤负担。
Int J Cancer. 2014 Sep 15;135(6):1319-29. doi: 10.1002/ijc.28787. Epub 2014 Mar 3.
引用本文的文献
1
The Role of Osteoprotegerin in Breast Cancer: Genetic Variations, Tumorigenic Pathways, and Therapeutic Potential.骨保护素在乳腺癌中的作用：基因变异、致瘤途径及治疗潜力
Cancers (Basel). 2025 Jan 21;17(3):337. doi: 10.3390/cancers17030337.
2
Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation.通过肿瘤血管和微环境正常化改善乳腺癌治疗：改善药物灌注和纳米载体渗透的范式转变
Drug Deliv Transl Res. 2025 Feb;15(2):389-406. doi: 10.1007/s13346-024-01669-9. Epub 2024 Jul 15.
3
Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.用于乳腺癌的非传统及研究性正电子发射断层显像（PET）放射性示踪剂：一项系统评价
Front Med (Lausanne). 2022 Apr 12;9:881551. doi: 10.3389/fmed.2022.881551. eCollection 2022.
4
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.一项Ib期多中心剂量递增研究，评估多胺类似物PG-11047与吉西他滨、多西他赛、贝伐单抗、厄洛替尼、顺铂、5-氟尿嘧啶或舒尼替尼联合用于晚期实体瘤或淋巴瘤患者的疗效。
Cancer Chemother Pharmacol. 2021 Jan;87(1):135-144. doi: 10.1007/s00280-020-04201-1. Epub 2020 Nov 19.
5
Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy.斑马鱼异种移植作为贝伐珠单抗癌症治疗的快速筛选平台。
Commun Biol. 2020 Jun 10;3(1):299. doi: 10.1038/s42003-020-1015-0.
6
A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy.对于正在接受激素治疗且临床获益的转移性乳腺癌患者，在一线激素治疗的基础上增加一种新的免疫治疗方案。
J Mol Med (Berl). 2020 Mar;98(3):375-382. doi: 10.1007/s00109-020-01881-3. Epub 2020 Jan 29.
7
Inhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden.抑制血管内皮生长因子和血管生成素-2以减轻乳腺癌脑转移负担。
Front Pharmacol. 2017 Apr 11;8:193. doi: 10.3389/fphar.2017.00193. eCollection 2017.
8
Anti-angiogenesis therapy and gap junction inhibition reduce MDA-MB-231 breast cancer cell invasion and metastasis in vitro and in vivo.抗血管生成疗法和间隙连接抑制可在体外和体内降低MDA-MB-231乳腺癌细胞的侵袭和转移能力。
Sci Rep. 2015 Jul 28;5:12598. doi: 10.1038/srep12598.
9
In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line.在体外，通过抑制 VEGF 来观察人骨转移前列腺癌细胞系 LNCaP 衍生 C4-2B 细胞的转移行为。
J Exp Clin Cancer Res. 2012 May 1;31(1):40. doi: 10.1186/1756-9966-31-40.
10
Antiangiogenic therapy of breast cancer: how did we get here?: the road not taken.乳腺癌的抗血管生成治疗：我们是如何走到这一步的？：未选择的道路。
Clin Transl Oncol. 2011 Nov;13(11):765-6. doi: 10.1007/s12094-011-0730-x.
本文引用的文献
1
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.贝伐珠单抗联合多西他赛对比安慰剂联合多西他赛用于人表皮生长因子受体 2 阴性转移性乳腺癌一线治疗的 III 期研究。
J Clin Oncol. 2010 Jul 10;28(20):3239-47. doi: 10.1200/JCO.2008.21.6457. Epub 2010 May 24.
2
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.来曲唑联合贝伐珠单抗治疗转移性乳腺癌的可行性研究。
J Clin Oncol. 2010 Feb 1;28(4):628-33. doi: 10.1200/JCO.2009.21.8784. Epub 2009 Oct 19.
3
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.E2100的独立评估：一项贝伐单抗联合紫杉醇对比紫杉醇治疗转移性乳腺癌女性患者的III期试验
J Clin Oncol. 2009 Oct 20;27(30):4966-72. doi: 10.1200/JCO.2008.21.6630. Epub 2009 Aug 31.
4
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.用强效肿瘤血管生成抑制剂进行短期治疗后转移加速。
Cancer Cell. 2009 Mar 3;15(3):232-9. doi: 10.1016/j.ccr.2009.01.021.
5
RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer.RIBBON 1和RIBBON 2：贝伐单抗联合标准化疗用于转移性乳腺癌的III期试验。
Clin Breast Cancer. 2008 Aug;8(4):370-3. doi: 10.3816/CBC.2008.n.045.
6
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.紫杉醇联合贝伐单抗与单纯紫杉醇治疗转移性乳腺癌的比较
N Engl J Med. 2007 Dec 27;357(26):2666-76. doi: 10.1056/NEJMoa072113.
7
Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter.体内大鼠子宫基因表达的染色质免疫沉淀分析：雌激素诱导雌激素受体α和缺氧诱导因子1募集至血管内皮生长因子启动子。
Mol Endocrinol. 2005 Aug;19(8):2006-19. doi: 10.1210/me.2004-0388. Epub 2005 Mar 17.
8
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.卡培他滨与贝伐单抗联合卡培他滨治疗既往接受过治疗的转移性乳腺癌患者的随机III期试验
J Clin Oncol. 2005 Feb 1;23(4):792-9. doi: 10.1200/JCO.2005.05.098.
9
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.BAY 43 - 9006具有广谱口服抗肿瘤活性，作用于参与肿瘤进展和血管生成的RAF/MEK/ERK信号通路及受体酪氨酸激酶。
Cancer Res. 2004 Oct 1;64(19):7099-109. doi: 10.1158/0008-5472.CAN-04-1443.
10
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.一项在既往接受过治疗的转移性乳腺癌患者中进行的贝伐单抗Ⅰ/Ⅱ期剂量递增试验。
Semin Oncol. 2003 Oct;30(5 Suppl 16):117-24. doi: 10.1053/j.seminoncol.2003.08.013.
Zotero 插件